Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.
Salome Bwayo WeaverHelen AkinwaleNkem P NonyelLa'marcus T WingatePublished in: Expert review of hematology (2024)
Voxelotor resulted in a clinically significant difference in the percent change of hemoglobin from baseline to 3 months.
Keyphrases